Database

Biomedical artificial intelligence (AI) increasingly relies on heterogeneous data sources, yet differences in data structure, terminology, evidence quality, and provenance complicate their integration into reliable knowledge resources. Here, we develop an evidence-aware framework for processing and integrating heterogeneous pharmacovigilance data from FDA Adverse Event Reporting System (FAERS) reports, biomedical literature, clinical trials, and electronic health records in Mass General Brigham. The framework combines large language model (LLM)-based information extraction, ontology-driven semantic normalization, cross-source evidence assessment, statistical and machine learning-based prioritization, and ingredient-based adverse drug event (ADE) relationship inference to transform heterogeneous evidence into a structured and evidence-based knowledge resource. The constructed knowledge system contains 11,588 drug nodes, 44,843 ingredient nodes, 3,275 ADE nodes, 993 indication nodes, and more than 2.47 million relationships, with each drug-ADE relationship assigned a confidence score. We further developed a drug-level web interface for accessing the knowledge resource and validated its utility in downstream AI tasks. Specifically, incorporating the developed knowledge resource improved the comprehensiveness, relevance, and overall quality of LLM-based drug-specific ADE synthesis and improved the precision and F1 score of clinical ADE relation extraction. These results demonstrate that AI-assisted processing combined with evidence-aware curation can transform heterogeneous biomedical evidence into reusable, AI-ready knowledge with explicit provenance and evidence strength information. The framework provides a general strategy for integrating heterogeneous biomedical data to support reproducible knowledge construction and downstream biomedical AI applications.

Clinical records preserve patient findings and final recommendations but rarely capture how specialists select evidence, develop alternative interpretations, disagree, and converge on a management strategy. We describe a dataset derived from ten retrospectively selected, completed cases of histologically confirmed colorectal cancer. For each case, an administrator uploaded de-identified textual clinical records to an authenticated web-based annotation platform. A medical oncologist, surgical oncologist, and radiation oncologist, each with more than ten years of clinical experience, independently linked relevant source fragments to patient-specific interpretations and documented clinical problems, differential hypotheses, uncertainty, and diagnostic and treatment strategies. After the three records were locked, a large language model generated candidate questions for review by the tumour-board chair. The four physicians then discussed each case online; recordings were automatically transcribed and verified by two medical residents. The dataset comprises 30 source-linked specialist reasoning records, 10 verified case-level discussion transcripts, 10 final tumour-board decisions, and associated provenance and quality-control metadata. It supports research on evidence-grounded reasoning, cross-specialty disagreement, multidisciplinary decision-making, and multi-agent clinical decision support.

Background: Cost-effectiveness analyses (CEA) built on simulation models are usually delivered through project-specific scripts. Each new model, and often each new question, rebuilds the same scaffolding: parameter management, calibration, base-case analysis, sensitivity analysis and export. This is costly, and is where traceability between an estimate and the model version producing it is lost. We present THALASSA, a web application providing this infrastructure once, for any model satisfying a small programming contract. Methods: A simulation model is connected by one file implementing a fixed contract of R functions that determine its behaviour. THALASSA exposes the complete CEA workflow in a browser: a generated overview of the connected model, parameter editing, calibration, base-case comparison with the efficiency curve, and deterministic and probabilistic sensitivity analysis at a willingness-to-pay threshold, each with timestamped file export carrying the parameter values it was run with. Every session is bound to a repository version, so results carry their generating model version. Results: We demonstrate THALASSA on two public models of contrasting difficulty: a simple tutorial model and a generic cancer screening model with two competing natural-history pathways and a 21-dimensional calibration deliberately built to be more complex. Both ran on the same unmodified setup, implementing the same contract, with no code changes. Conclusions: Separating analysis infrastructure from model logic makes the CEA workflow reusable across projects and reproducible by construction. A modelling team can move from a versioned repository to audit-ready, exportable CEA outputs without writing analysis code. The integration effort does not grow with model size and one installation serves unrelated projects.

Large language models (LLMs) are increasingly evaluated for clinical tasks, but safe use requires reliable uncertainty estimates as well as high accuracy. We tested eight general-purpose LLMs on 100 validated neurology board-style multiple-choice questions and compared three confidence signals: self-reported confidence, critique-implied confidence from an independent model instance, and consistency-based confidence from repeated sampling. Accuracy varied from 45% (Llama 3.1 8B) to 92% (Gemini 3 Flash/Pro), but confidence was generally overestimated, particularly in lower-accuracy models. Consistency-based confidence provided the best discrimination between correct and incorrect answers (pooled AUROC 0.74), outperforming self-report, although calibration differences between methods were not significant. Calibration should therefore be reported alongside accuracy when clinical LLMs are evaluated.

Introduction: Primary care electronic health records (EHRs) are an important resource for health research, but death recording in primary care EHRs may be incomplete or differ from Office for National Statistics (ONS) death registrations. We used OpenSAFELY-TPP to assess the completeness and concordance of death recording and provide recommendations for using date-of-death information. Methods: Using linked primary care EHRs and ONS death registrations, we assessed whether ONS-registered deaths from 2020-2025 had a primary care date of death and, where present, calculated the difference between dates. Where a primary care date was absent, we assessed death-related SNOMED CT codes. Analyses were conducted overall and by year, population subgroup, and general practice. We also examined GP registration end dates and primary-care-recorded deaths without a corresponding ONS record, including monthly patterns near the data extraction date. Results: Among 1,409,275 ONS-registered deaths, 88% had the same date recorded in primary care and 8% had no corresponding primary care date. Among 1,324,995 deaths recorded in primary care, <2% had no corresponding ONS record. Deaths recorded in only one source were more frequent among people aged <45 years and those from Mixed, Asian or Asian British, Black or Black British, and Chinese or Other ethnic groups. ONS-only dates were also more frequent in London and the West Midlands. Primary-care-only deaths increased close to date of data extraction, reaching 7% in February 2026. Same-day GP deregistration increased from 9% in 2020 to 85% in 2025. Conclusions: Death recording in primary care EHRs showed high completeness and concordance with ONS registrations, but discrepancies remained for recent deaths and some population groups. Data recency and population-specific completeness should therefore be considered when using linked mortality data for research.

Background. Research data enclaves such as the All of Us Research Program do not allow participant-level data, or models fitted to them, to leave, which makes it hard to deliver case-finding models, which flag patients with possibly uncoded conditions for clinician review, to patients and clinicians. Objectives. We describe and technically evaluate a system that fits models outside an enclave from released summary counts and delivers them through standard health information technology interfaces. Methods. We exported dissemination-compliant summary counts from the All of Us Researcher Workbench and, outside the enclave, fitted versioned models for Long COVID, chronic fatigue, fibromyalgia, endometriosis, Lyme disease, lupus, migraine, depression, and anxiety. A model contract (a model file and a written specification), a Python reference implementation, and synthetic Fast Healthcare Interoperability Resources (FHIR) test patients define the expected outputs. One JavaScript scorer runs in a patient demonstration, a SMART on FHIR clinician application, and a CDS Hooks service. An atlas displays aggregate results. We evaluated the system on synthetic records with automated tests, cross-implementation output comparison, launches through the public SMART sandbox, and a counterexample review of the scoring and display rules. Results. The deployed Long COVID model had an area under the receiver operating characteristic curve of 0.67 in a random validation split. The eight self-report models reached 0.61 to 0.82 in identifying self-reporters without a code. The JavaScript scorer reproduced all 162 reference outputs exactly, and all 437 automated tests passed. A counterexample review found 5 classes of failure, including scoring ineligible patients and treating unavailable data as absent, all fixed and added as tests. Conclusions. Models fitted from released summary counts can be delivered through FHIR, SMART on FHIR, and CDS Hooks with reproducible scoring on synthetic records. Real-record interoperability, usability, and prospective clinical performance remain to be evaluated.

Neurologic autoantibody cell-based assay images are difficult to interpret when fluorescence is weak, focal or dominated by background signal. We developed a visual artificial intelligence overlay that transfers detected cell boundaries from the structural channel to the antibody-staining image and evaluated standalone model concordance and its association with reader classifications. The analysis used 2 763 records for model development and 499 held-out records spanning 14 antibody targets. Four readers assessed the held-out records first without assistance and then with the boundary overlay and model category available. The selected model agreed with the reader-derived three-class reference in 85.2% of records, but recall was lowest for weak-positive or equivocal records. Reader agreement increased in the assisted session, and almost all revised ratings moved towards the model category. The combined display may support consistent visual review while also creating a risk of model-directed anchoring; its role as a second-read aid requires independent validation.

Purpose: Accurately capturing a patient's health journey is essential for ensuring the validity of scientific and public health studies. Electronic health records (EHR) and administrative claims are commonly used in healthcare research, albeit separately. Previous research has demonstrated that EHR and claims capture different aspects of patient history and care, potentially introducing bias when used alone. In this study, we leveraged the largest public US EHR resource, the National Clinical Cohort Collaborative (N3C), alongside Centers for Medicare & Medicaid Services (CMS) claims data to compare their information coverage and agreement. Methods: We integrated N3C EHR and CMS data to create one cohesive dataset and quantified the proportion of key variables present in EHR alone, CMS alone, and the overlap present in both data sources. Overlap in information coverage was quantified pre- and post-landmark diagnosis of COVID-19. To evaluate the impact of data coverage differences, we conducted a case study evaluating the effect of COVID-19 vaccination on ischemic stroke using both data sources alone and in combination. Results: CMS data helped identify many individuals that were duplicated among EHR identifiers. Examination of the overlap showed that CMS data more completely captured conditions, while EHR data more completely captured medications after COVID-19 diagnosis. Some variables exhibited marked differences over time after landmark COVID-19 diagnosis. Using target trial emulation and self-controlled case series methods, we found that data capture variations altered effect estimates: EHR data alone yielded lower risk of ischemic stroke after vaccination in the target trial emulation (odds ratio 0.47, 95% CI 0.28-0.79), with a smaller, non-significant reduction in the self-controlled case series (incidence rate ratio 0.81, 95% CI 0.64-1.02), whereas analyses using CMS data alone or both sources combined yielded estimates close to the null in both designs. Conclusions: Results indicated that when using either a national database combining multiple EHR sources, or CMS claims data alone, patients' medical histories are less completely captured compared to when these data sources are combined. Case study results highlighted the value of combining data sources for not only yielding fuller patient health histories and valid scientific results, but for identifying and explaining biases that may emerge in research studies that rely on a single data source.

Background and Objectives Huntington's disease is a rare neurodegenerative disease in which optimizing clinical trial design is essential. Although baseline characteristics are known to predict disease progression, the statistical efficiency gains achievable by formally integrating prognostic predictions into trial analyses have not been systematically quantified. We aimed to benchmark prognostic modeling approaches, quantify the trial efficiency gains from prognostic covariate adjustment, and deliver a ready-to-deploy framework for immediate implementation. Methods: We developed a two-step modeling pipeline using longitudinal Enroll-HD natural history data (NCT01574053) to train nine machine learning algorithms to predict disease progression across five UHDRS endpoints. For this, we used 16 predictive baseline covariates representing stage of disease (baseline score levels), disease specific (CAP, CAG length), demographics and co-medication use that could be quantified in one clinical visit. For Total Function Capacity (TFC), frequently used as a primary endpoint in clinical trials, we also devised a minimal prognostic model based on 6 covariates. Model performance was tested using the placebo arm of the GENERATION HD1 phase 3 trial (NCT03761849). Results: Models were trained on 16,398 Enroll-HD participants and tested on 260 participants from the GENERATION HD1 placebo arm. Models that take into account nonlinear relationships between the covariates showed no performance advantage over linear-based models on the test set. For TFC, a minimal six-covariate linear prognostic model performed on par with the full 16-feature model. Adjusting for the prognostic score increased the signal-to-noise ratio across different trial visits by 8-18%, raising statistical power from 80% to up to 90% at a fixed sample size, or, equivalently, reducing required sample size by 15-28% compared to unadjusted analyses (no covariate adjustment). Compared to routinely used covariate adjustments (including baseline score, age, CAG repeat length, and CAP score), adjusting for a prognostic score consistently delivered meaningful additional efficiency gains. Discussion: Prognostic covariate adjustment using a simple six-covariate linear score derived from a single baseline visit yields meaningful gains in statistical power for HD clinical trials, while remaining fully embedded within standard, regulator-accepted analysis frameworks. This approach offers a practical and immediately deployable tool to improve trial design.

Background HPV-vaccination prevents HPV-related cancers, but uptake remains suboptimal. In the Netherlands, a catch-up campaign invited 18-27-year-olds for an additional cost-free opportunity to initiate or complete their HPV-vaccination in 2023-2024, which led to 24% of this invited population getting vaccinated. As young adults increasingly seek health information online, understanding online questions, concerns and misinformation in response to the campaign may help improve future vaccination efforts. Supplemental to overall evaluation of the vaccination campaign, we piloted online social listening processes to generate an insight report for Public Health Service (PHS) Amsterdam. Objective This study piloted online social listening processes at the PHS Amsterdam to identify actionable insights into questions, concerns and misinformation surrounding the HPV-vaccination catch-up campaign among young adults. Methods Upon inventory of potential platforms and data sources, a retrospective online social listening analysis was conducted across the platforms Instagram, Facebook, and X, collecting data from PHS, the National Public Health Institute for Public Health and the Environment (RIVM), the Dutch public broadcasting foundation (NOS), and LINDA.meiden sources from January 1, 2023, to June 1, 2024. Publicly available posts, comments, and engagement concerning HPV-vaccination were manually collected, and inductively coded. Themes were assessed for risk, based on expected potential harm and observed reach, and used to develop recommendations. Results A total of 821 posts and 5157 comments were collected and analysed. Ten recurring themes were identified across varying levels of risk. Two themes were classified as high risk: an information gap regarding the effectiveness of HPV-vaccination and concerns about the transparency on HPV-vaccine side effects. Three themes were classified as medium risk: questioning HPV-vaccine effectiveness under certain circumstances, reduced general vaccine trust following COVID-19, and accessibility issues related to vaccination locations and service times. Two themes were classified as neutral risk: questions regarding eligibility criteria for the campaign and calls for broader HIPV-prevention measures. Finally, three low risk themes concerned questions regarding HPV-vaccine brand specifics, campaign choices, and questions about scheduling or rescheduling HPV-appointments. Comments also referred to subsequent information sources, including reliable sources (public health institutes), false narratives and misinformation. Recommendations focused on addressing questions and information gaps (i.e. improving HPV risk perception and providing more detailed HPV-vaccine information), improving communication about HPV-vaccination, and reducing practical barriers to vaccination. Conclusions Manual social listening across selected online sources provided actionable insights into the public discourse during the HPV-vaccination catch-up campaign. Results mostly reflected questions, concerns and information gaps. Although some themes were critical of HPV-vaccination, false narratives and misinformation did not dominate the discourse. Recommendations aim to reduce practical barriers and address information needs. This pilot showed that online social listening can be effectively implemented even with limited resources.

The gut-brain axis has emerged as a critical modulator in neurological diseases, including stroke. While acute post-stroke dysbiosis is well established, it remains unclear whether these alterations persist long-term and can be therapeutically modulated. This study addresses this gap through integrated metagenomic and metabolomic profiling in two independent clinical stroke cohorts, complemented by experimental models. Experimental stroke induced persistent changes in gut microbiota composition and altered short-chain fatty acid profiles. In patients, microbiota composition remained distinct from controls up to three months after ischemic stroke or transient ischemic attack (TIA), accompanied by persistent reductions in propionic and valeric acid and reduced abundance of Prevotella-associated microbial signatures. We performed a randomized, double-blind interventional trial (PRISE) testing a multispecies probiotic versus placebo, using household members as additional controls. Probiotic intervention led to microbiome compositional changes with increased abundance of beneficial taxa and significantly improved functional recovery. The tested probiotic strains showed anti-inflammatory and antioxidant effects in vitro. These findings suggest that targeted modulation of the microbiome represents a promising therapeutic avenue to improve chronic stroke recovery, warranting validation in larger Phase III clinical trials.

Background: This study compared functional and cognitive trajectories in older women treated for early breast cancer with matched women without cancer. Methods: Data were derived from two Dutch cohorts: the CLIMB study (women aged 75 years and older with operable breast cancer) and the ISCOPE study (community-dwelling women aged 75 years and older without cancer). Breast cancer patients were matched 1:2 to controls on age and baseline functional or cognitive status. Functional status was assessed using the Groningen Activity Restriction Scale (GARS), and cognitive function using the Mini-Mental State Examination (MMSE). Longitudinal changes over 12 months were analyzed using both unadjusted and confounder-adjusted linear mixed models. Results: 168 breast cancer patients and 336 matched breast cancer-free controls were included with a mean age of 80 years. Most breast cancer patients had stage 0-I or II disease and received surgery and/or radiotherapy; 48% received adjuvant endocrine therapy, chemotherapy was rare (<1%). At baseline, both cohorts were comparable in age and functional or cognitive status, although there was a higher comorbidity burden in the control cohort. No significant differences in functional or cognitive decline were observed between the cohorts over 12 months. Conclusions: In older women, early breast cancer and its treatment did not lead to accelerated decline in functional status or cognitive function within the first year compared to matched older women without cancer. These findings suggest that, for relatively fit older patients, breast cancer treatment may not accelerate functional decline in the short term.

Stroke is a leading cause of mortality and disability in Uganda, with a prevalence of approximately 2.5% and a 25-30% 30-day mortality rate, exacerbated by limited access to predictive tools and advanced diagnostics. Machine learning (ML) offers potential for early stroke risk stratification, but its application in resource-constrained settings like Uganda requires tailored models and rigorous performance evaluation, as well as assessment of misclassification patterns. This study aimed to develop and internally validate an ML-based predictive model for stroke using clinical and socio-demographic characteristics among patients at Mulago National Referral Hospital (MNRH) and residents of Wakiso District, Uganda, identify key predictors and assess misclassification patterns to enhance targeted prevention. A retrospective case-control study utilized secondary data from 1,016 participants (254 stroke cases, 762 controls) across three prior studies conducted between 2006 and 2015. Eight ML algorithms were evaluated using 5-fold cross-validation, with performance metrics including accuracy, sensitivity, positive predictive value, F1-score, and area under receiver operator characteristics curve (AU-ROC). McNemars test compared model classification performance of the top 2 models. Feature importance identified key predictors, and misclassification patterns were analyzed using classification matrix and line graphs. The Random Forest (RF) model achieved the highest performance (95.18% accuracy, 90.10% F1-score, 97% AU-ROC). McNemars test confirmed RFs superior classification (p=0.01). Age, systolic blood pressure, total cholesterol, and waist-hip ratio were the top drivers of RF stroke predictions. RF misclassified 8.3% of stroke cases and 3.3% of non-stroke cases, due to overlaps in risk profiles (e.g., lower cholesterol, systolic blood pressure and age in false negatives). The RF model demonstrates strong potential for stroke risk prediction in Uganda, leveraging routine data to prioritize high-risk individuals. Misclassification analysis highlights areas for model refinement, supporting its potential for integration into clinical workflows for early intervention and stroke prevention in resource-limited settings. Future external validation across diverse populations is recommended.

INTRODUCTION: Alzheimer's disease (AD) begins with cerebral amyloid-beta (A{beta}) deposition decades before clinical symptoms. While the microbiota-gut-brain axis has been implicated in AD, its role in this preclinical phase remains unclear. We examined potential links between gut microbiome features and presymptomatic cerebral A{beta} burden. METHODS: Asymptomatic individuals (n=101, median age 70.0 years, 53% female) underwent cognitive assessment, cerebral A{beta} quantification, and stool metagenomic sequencing. Associations between microbial characteristics and A{beta} levels were performed using multivariable-adjusted ordinal logistic regression. RESULTS: Gut microbiota composition varied with A{beta} levels (p(perm)=0.03, R2=0.014). Higher A{beta} was associated with increased Alistipes communis, and decreased Anaerotignum faecicola and Eubacterium rectale, abundance (q<0.001). A{beta}-associated microbiome traits corresponded to lower biosynthetic capacity for {gamma}-aminobutyric acid, and systemic regulators of immunity and autophagy (q<0.01). DISCUSSION: Early A{beta} accumulation is associated with distinct gut microbial signatures and reduced neuroactive metabolic potential, identifying targets for potential preclinical AD intervention.

Background: Blood-based biomarkers (BBMs) may facilitate early detection of Alzheimers disease (AD), yet data in Latino populations remain limited. We examined associations of plasma biomarkers with cognition and depressive symptoms in Spanish-speaking Latino older adults enrolled in the Boston Latino Aging Study (BLAST). Methods: Baseline data from 122 older adults without dementia were analyzed. Plasma AB42/40, brain-derived phosphorylated tau (p-tau) 217, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured using NULISA. Cognition was assessed with the Latin American Spanish version of the Preclinical Alzheimers Cognitive Composite (LAS-PACC5) and depressive symptoms with the Geriatric Depression Scale (GDS). Regression models were adjusted for age, sex, and education. Results: Cognitively impaired participants had higher p-tau217 and GFAP than cognitively normal participants. Higher p-tau217 and GFAP were associated with poorer LAS-PACC5 performance, while higher NfL was associated with greater depressive symptoms. AB42/40 showed no significant associations. Conclusions: Distinct biomarker associations with cognitive and emotional functioning support further longitudinal evaluation of BBMs for risk characterization in Latino older adults and potential disease monitoring applications.

DNA methylation-based classification is increasingly a cornerstone of CNS tumor diagnostics. Recently,nanopore sequencing enables very rapid methylation profiling to support surgical decision making. Time-constrained sequencing yields sparse methylation profiles, necessitating specialized classifiers for accurate predictions. All publicly available sparse-profile classifiers rely on a single reference set of only 2,801 samples published in 2018 and its accompanying classification system. Here we present Sturgeon V2, trained on nearly 10,000 methylation profiles assembled from a range of public repositories and collaborations. To harmonize differences in tumor class labels, we developed an iterative semi-supervised relabeling strategy with a two-tiered concordance filter. We demonstrate that this filtering is essential for optimal performance. Compared to Sturgeon V1, we further redesigned the classifier architecture to provide more stable, and consistent confidence estimates while accumulating sequencing data and we introduce an updated class system including new classes, such as meningioma subtypes, PATZ- fusion neuroepithelial tumors and PLAG1/2-amplified embryonal tumors. In a retrospective intraoperative cohort of 94 pediatric cases, Sturgeon V2 was confidently correct in 85 cases (Sturgeon V1: 78) with one confident misclassification, and in simulated sequencing runs (n=1880) reduced the error rate among confident calls from 7.1% to 2.8%, outperforming publicly available alternatives. Sturgeon V2 is the first openly available, locally executable classifier for sparse methylation profiles trained beyond the 2018 reference era.

Background: Neoadjuvant chemotherapy (NACT) facilitates de-escalation of breast and axillary treatment in breast cancer, but pathological responses may differ between the primary tumour and axillary lymph nodes. Understanding differential response is crucial for de-escalation strategies. Methods: This single university hospital retrospective study analysed operable breast cancers (cT1-cT3, cN0-cN3) treated with NACT (January 2013-November 2020). Two-tailed Fishers exact test or the Chi-squared test (for 2x2 comparisons) analysed concordance between breast and axillary pathological responses; Cox proportional hazards regression ascertained predictors of distant recurrence and survival; and logistic regression ascertained predictors of complete axillary response. Results: Among 413 patients (cN0=229; cN+=184) with a median age of 51, pathological response concordance between the breast and axilla was 81% (both pCR, 22.2%; concurrent residual disease, 58.8%). The cN0 group had a significantly higher ypN0 rate in breast pCR versus non-pCR (97.1% vs 80.8%, p<0.001). cN+ had axillary pCR concordant with breast pCR, compared to only 16.5% with residual breast disease. Breast pCR was the most significant predictor of axillary pCR (OR=11.6, p<0.001). Axillary pCR was highest in ER-/HER2+(66.7%) and triple-negative(46.9%) subtypes. Residual axillary disease was independently associated with the worst breast cancer-specific (HR=7.13, p=0.006) and overall Survival (HR=3.32, p=0.029). Kaplan-Meier analyses showed a trend towards worse survival outcomes with axillary residual disease, even with a breast pCR. Conclusions: In this limited series, breast pCR predicts axillary pCR in cN0 and cN+, particularly in HER2-positives and triple-negatives, supporting axillary de-escalation strategies in selected patients stratified by careful assessment of disease at the end of NACT.

Background and Objective: The volume of patient portal messages has grown substantially and artificial intelligence (AI) can support clinical staff and improve the timeliness of patient care. Our objective is to test if an AI tool for managing the electronic inbox In-Basket reduces response times to patient portal messages in neurology. Methods: We conducted an implementation study from January to May 2026 in the neurology department at two clinical sites within a regional medical system. A single AI tool was implemented to auto-categorize and auto-route all patient messages received in the electronic inbox. The tool also generates optional draft replies to messages. Primary process measures were the median weekly time (hours) from message creation to the first action and to closure. Impact was analyzed using a controlled interrupted time-series (ITS) design, comparing message-volume-matched control divisions. Results: Among 24,142 messages analyzed, pre-intervention median weekly time to first action was 11.3 hours [IQR: 5.6, 15.1] (Site A) and 16.1 hours [IQR: 13.8, 19.0] (Site B), falling post-intervention to 1.0 hour [IQR: 0, 3.1] (Site A) and 0.6 hours [IQR: 0.2, 2.4] (Site B). Controlled interrupted time-series analysis showed a significant immediate differential level change in median weekly hours to first action at Site A (-92.5%, 95% CI: -97.5% to -78.0%), and a significant downward trend at Site B (-43.5%, 95% CI: -65.2% to -8.2%). Changes in time to closure were directionally favorable but not statistically significant at either site. There was low use of the generated draft replies, only 0.5% at Site A and 3% at Site B. Discussion: Implementation of AI-assisted message categorization and routing was associated with a substantially reduced initial action time for patient In-Basket messages in Epilepsy. The utilization of AI-generated draft-replies to messages was low. These findings support the feasibility and effectiveness of AI-augmented workflows to improve inbox management.

Background: The first thousand days are a sensitive window for child health and social health inequalities. When routine care falls short, parents of young children turn to online sources and, recently, to generative artificial intelligence (AI). Evidence on their concerns, child-health literacy, and AI use is scarce. Objective: To describe health informational needs and concerns, child-health literacy, and use of AI for child-health questions, including differences by parental role and parity, among parents of young children. Methods: In this cross-sectional study, two anonymous self-administered online questionnaires were disseminated through a digital health application between May 12 and June 11, 2026, to French-speaking parents of at least one child aged 0 to 47 months in France. Questionnaire 1 covered unmet information needs, concerns across 16 topics, perceived intra-couple concordance, and confidence in routine care. Questionnaire 2 covered a four-item child-health literacy quiz and AI use (frequency, topics, 12-month trend, barriers, trust conditions, perceived effect on consultations, and disclosure). Results: In total, 12,634 parents responded (Questionnaire 1, n=5,410; Questionnaire 2, n=7,224), mostly mothers (94.6% and 92.9%). Most (61.8%) had searched for information without finding a clear, reliable answer, selecting a median of 4 (Interquartile range [IQR] 3-7) over 16 topics. Leading concerns were sleep (51.3%), nutrition (48.1%), and education (i.e., upbringing and behavior) (47.8%). Mothers were nearly twice as likely as fathers to select accident prevention (26.5% vs 16.3%) and parental mental health (38.7% vs 28.6%); first-time parents selected most topics more often than experienced parents, most markedly dental hygiene (43.8% vs 27.6%). The median child-health literacy score was 3 (IQR 3-4) on a 0-to-4 quiz, with 19.9% of parents scoring 2 or below; tooth-brushing age was the weakest item (68.4% correct). Mothers outscored fathers on every item. More than half of parents (54.2%) had used AI for a child-health question, 11.2% weekly; among those reporting a trend, 68.3% had increased AI use for child-health questions over the year and 6.2% decreased it. The main barriers to AI use were a preference for professionals (55.9%) and reliability concerns (48.7%); trust depended most on medical oversight of the tool (76.6%). AI use appeared additive, with 66.8% reporting no change in healthcare visit frequency. One third (35.5%) had told an AI something shared with neither a professional nor their network, rising to 64.1% among regular users. Conclusions: Parental informational needs were widespread and frequently unmet. AI has become a common and fast-rising source for child-health questions, at times a confidential one, used alongside rather than instead of professionals. Child-health literacy was generally high but uneven, with oral health the clearest gap. Strengths include the sample size and early-generative-AI timing; limitations include the cross-sectional design, self-report, digital-recruitment selection bias, and the small proportion of fathers.

Importance: Conditions that are hard to diagnose, several more common in women, may be missing from electronic health records (EHRs), hiding patients from research cohorts and case finding. Objective: To measure how often the EHR contains a diagnosis code for chronic conditions that participants report, and to compare this with national survey benchmarks. Design, Setting, and Participants: This cross-sectional study used the All of Us Research Program Registered Tier Dataset v9. Participants were adults with EHR visits in both 12-month periods from July 2021 to June 2023 who completed a health history survey. We analyzed the data in October 2026. Exposures: Self-reported clinician diagnosis of 10 conditions with ongoing visits or treatment, as well as sex at birth, race and ethnicity, age, and years of EHR records. Main Outcomes and Measures: Share of participants reporting current care who had a qualifying diagnosis code, alone and relative to hypertension and type 2 diabetes, and the ratio of age-standardized coded shares to national survey prevalence. Results: Of 161,480 respondents, 114,610 (73,870 female [64.5%], median [IQR] age 63 [50-72] years) had at least 5 years of EHR records before the survey. Among those reporting current care, 84.6% (95% CI, 84.2%-85.0%) with hypertension and 87.0% (95% CI, 86.5%-87.6%) with type 2 diabetes had a code, compared with 41.3% (95% CI, 38.9%-43.8%) for endometriosis, 39.4% (95% CI, 34.3%-44.8%) for Lyme disease, and 24.4% (95% CI, 23.2%-25.6%) for chronic fatigue. Counting ICD-9-CM and other mapped codes, 55.3%, 51.5%, and 28.3%, respectively, had any qualifying record. Women had lower coded shares than men for hypertension, type 2 diabetes, obesity, depression, and anxiety (crude ratios 0.93-0.96, within-health-system ratios 0.98-1.02) and higher shares for migraine and fibromyalgia (within health systems, 1.11 [95% CI, 1.07-1.15] and 1.41 [95% CI, 1.29-1.57]). Age-standardized coded shares among active patients were 1.1 to 2.4 times national prevalence of the same self-reported diagnoses. Conclusions and Relevance: In this cross-sectional study, fewer than half of participants reporting ongoing care for chronic fatigue, Lyme disease, or endometriosis had a qualifying ICD-10-CM code. Linking each participant's report to their own record measured this gap directly.